A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy
Details
Publication Year 2019-02-04, Volume 9, Issue #1, Page 1225
Journal Title
Scientific Reports
Publication Type
Journal Article
Abstract
Both targeted therapy and immunotherapy have been used successfully to treat melanoma, but the development of resistance and poor response rates to the individual therapies has limited their success. Designing rational combinations of targeted therapy and immunotherapy may overcome these obstacles, but requires assessment in preclinical models with the capacity to respond to both therapeutic classes. Herein, we describe the development and characterization of a novel, immunogenic variant of the Braf(V600E)Cdkn2a(-/-)Pten(-/-) YUMM1.1 tumor model that expresses the immunogen, ovalbumin (YOVAL1.1). We demonstrate that, unlike parental tumors, YOVAL1.1 tumors are immunogenic in vivo and can be controlled by immunotherapy. Importantly, YOVAL1.1 tumors are sensitive to targeted inhibitors of BRAF(V600E) and MEK, responding in a manner consistent with human BRAF(V600E) melanoma. The YOVAL1.1 melanoma model is transplantable, immunogenic and sensitive to clinical therapies, making it a valuable platform to guide strategic development of combined targeted therapy and immunotherapy approaches in BRAF(V600E) melanoma.
Publisher
Springer Nature
WEHI Research Division(s)
Immunology
PubMed ID
30718660
Open Access at Publisher's Site
https://doi.org/10.1038/s41598-018-37883-y
NHMRC Grants
NHMRC/1088703
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2019-03-13 08:04:17
Last Modified: 2019-03-13 09:12:47
An error has occurred. This application may no longer respond until reloaded. Reload 🗙